Viewing Study NCT00000180



Ignite Creation Date: 2024-05-05 @ 10:23 AM
Last Modification Date: 2024-10-26 @ 9:01 AM
Study NCT ID: NCT00000180
Status: COMPLETED
Last Update Posted: 2009-12-11
First Post: 1999-10-29

Brief Title: AIT-082 Phase 1B Study
Sponsor: National Institute on Aging NIA
Organization: National Institute on Aging NIA

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2005-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits

This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline Eight healthy older volunteers at two clinical sites were given single weekly rising doses of AIT-082 or placebo for 5 weeks were tested for side effects and absorption and underwent a battery of neuropsychological memory tests including word and number recall tests
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
3U01AG010483-08S2 NIH None httpsreporternihgovquickSearch3U01AG010483-08S2